U.S. moving to bolster vaccines, biologics surge capacity

Political controversy over government funding of viral countermeasures R&D is raising concerns in the public health community that the U.S. will not act to strengthen pandemic preparedness. A loan announced Friday that aims to create new manufacturing capacity for vaccines and critical measures could be a sign that the U.S. will not immediately lapse into complacency.

Biomanufacturing company National Resilience Inc. has received a $410 million 20-year loan from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC), to bolster its capacity to manufacturer biologics, vaccines and nucleic acids in the U.S. ...